Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd (GLMD) is a small-cap, clinical-stage biopharmaceutical company focused on developing treatments for metabolic and liver diseases, notably non-alcoholic steatohepatitis (NASH). With a market capitalisation of about $7.84 million, Galmed sits in the higher-risk segment of the market: progress depends heavily on clinical trial outcomes, regulatory decisions and the company’s ability to secure funding or partnerships. Investors should be aware that small biotechs can experience large price swings and potential dilution if additional capital is needed. Key things to watch are trial readouts, licensing deals, cash runway and management updates. This summary is educational and not personalised financial advice; whether this stock is suitable depends on your goals, timeframe and risk tolerance. Past events or promising science do not guarantee future returns, and investors should seek independent advice before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Galmed Pharmaceuticals' stock with a target price of $12, indicating potential growth.
Financial Health
Galmed Pharmaceuticals is showing strong cash flow and solid book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GLMD
MASH Stocks: Could Roche's Deal Spark More M&A?
Roche's $3.5 billion acquisition of 89bio for its liver disease drug highlights the growing MASH treatment market. This deal creates a potential tailwind for other biopharmaceutical companies developing therapies for liver and metabolic conditions.
Published: September 21, 2025
Explore BasketMASH Drug Developers Could Attract M&A in 2025
Roche's $3.5 billion deal to acquire 89bio for its late-stage liver disease drug highlights the immense commercial potential seen in the MASH treatment landscape. This move could trigger a wave of investment and further acquisitions, benefiting other biotech firms with promising therapies for metabolic disorders.
Published: September 19, 2025
Explore BasketMASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: September 18, 2025
Explore BasketWhich Pharma Stocks Could Follow Wegovy's Success?
Following the FDA's approval of Novo Nordisk's Wegovy for a common liver disease, this theme focuses on pharmaceutical companies developing treatments for metabolic disorders. This development opens a new market for weight-loss drugs and signals opportunity for firms with therapies targeting related conditions.
Published: August 21, 2025
Explore BasketGLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage focus
Progress hinges on trial results and regulatory review; positive readouts can be catalysts, though outcomes are uncertain.
Niche liver therapies
The company targets NASH and related metabolic liver conditions, a developing therapeutic area with unmet need and scientific complexity.
Volatile, high-risk stock
Small market cap means share prices can swing and funding needs may lead to dilution; suitable only for investors comfortable with speculative risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
